Aerie Announces US Launch of Rhopressa

Source: Aerie Pharmaceuticals

Aerie Pharmaceuticals announced that it has launched Rhopressa in the United States. Rhopressa is now in national and regional US pharmaceutical distributors, and patients have access to Rhopressa through their local pharmacies across the nation.

“We are pleased to announce the availability in the United States of Rhopressa, the first new drug class in more than 2 decades for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension,” Vicente Anido, Jr., PhD, Chairman and Chief Executive Officer, said in a company news release. “Our national sales force is fully trained, deployed, and already providing product information and samples to physicians. Formulary contracts for commercial insurance coverage in 2018 and Medicare Part D program coverage beginning in 2019 are in the final stages of being executed. In addition, through the availability of a co-pay savings card program, all patients covered by commercial insurance will have immediate access to Rhopressa. Aerie has also proactively engaged the major e-prescribing platforms to ensure physicians are able to prescribe Rhopressa electronically for their patients. We look forward to providing additional details as part of our business update during our first-quarter 2018 financial results call scheduled for May 8, 2018.”

Related Content